利拉鲁肽作为人GLP-1类似物,目前已知它可以通过延缓胃排空、抑制胃酸分泌以及刺激中枢中枢神经系统而增加饱食感进而减少能量的摄入,实现减轻体重的作用。 The effect of GLP-1 on weight: GLP-1 affects the gastrointestinal system and delays absorption of food. This is caused by several means, including ...
Glucagon-like peptide-1 (GLP-1) and protective effects in cardiovascular disease: a new therapeutic approach for myocardial protectionGLP-1Insulin resistanceHeartCardiovascular diseaseDiabetesGlucagon-like peptide-1 (GLP-1) is a member of the proglucagon incretin family implicated in the control of ...
( DPP-4) 抑制剂是近年上市的治疗 2 型糖尿病的新型药物.GLP-1 主要通过抑制心肌细胞凋亡,改善内皮细胞功能,减轻体重,降低血 糖,降低血压,改善心肌收缩力,舒张血管等直接或间接发挥其心脏保护作用,GLP-1 受体激动剂和 DPP-4 抑制剂对体重,血压和血脂等心血管危险因素有改善作用.GLP-1 受体激动剂和 DPP-4 ...
thisolatedperfusedratheartandwholeanimalmodelsofischaem ia/reperfusionwereused,withinfarctsizemeasuredastheendp ointofinjury.Inbothstudies,GLP-1addedbeforeischaemiadem onstratedasignificantreductionininfarctioncomparedwiththe valinepyrrolidide(aninhibitorofitsbreakdown)orsalinegro ups.Thisprotectionwasabolishedinthe...
and "heart protection". GLP-1R agonists can improve left ventricular ejection fraction, myocardial contractility, coronary blood flow, cardiac output, and endothelial function while reducing infarction size and overall risks for a cardiovascular event. Other functions of GLP-1 include increased glucose ...
GLP_1及其受体激动剂Exendin_4临床适应症的扩展
When one consumes GLP-1-boosting foods and supplements, one can activate GLP-1 receptors and obtain wide-ranging therapeutic effects, from weight control to heart protection. Lifestyle changes like exercise, stress reduction, and sleep can also optimize endogenous GLP-1 creation. Targeting this impo...
Furthermore, glucagon also possesses beneficial effects on multiple organs including the pancreas, kidney, heart, and brain [1]. Increased plasma glucagon (hyperglucagonemia) contributes directly to hyperglycemia in patients with type 2 diabetes (T2D) [3]. The incretin hormones glucagon-like peptide...
Am Heart J 2005;149:54-60. 校正相对风险 1 1 1 1.17 1.16 1.14 1.29 1.27 1.35 0.8 1 1.2 1.4 心血管死亡 心梗 全因死亡 分层1 分层 2 分层 3 男性 女性 95 95–103 103 87 87–98 98 腰围分层 (cm) 随内脏脂肪增加,心血管事件风险增高 HOPE研究, n=8802 HOPE: Heart Outcomes Protection ...
此外,liraglutide增强左心功能, 有助于减少HF事件,特别是在射血分数降低的 HF(heart failure with reduced ejection fraction, HFrEF)中.与对照组相比,利拉鲁肽组的每搏输 出量和心输出量明显增加[30,32-33].如果将SGLT2i和 GLP-1 RA一起给药,可能降低患者CVD病死率, 并可能在CVD事件上有更大的获益. ...